Please assess the completion status of the following clinical trial:

Trial Title: Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ≥ 18 years of age at start of screening~* CKD stage 3 or 4 defined by an eGFR 15 - 60 mL/min/1.73m2~* Not expected to start dialysis for 8 months~* Serum intact PTH \< 500 pg/mL during screening period~* On a stable ACE inhibitor/ARB regimen for 30 days prior to screening~Exclusion Criteria:~* History of any of the following diseases: congestive heart failure, MI within the last 6 months, cerebrovascular accident, significant valvular disease, malignancy~* Currently receiving erythropoiesis stimulating agent or IV iron therapy~* History of inflammatory/autoimmune disease~* History of polycystic kidney disease~* HIV positive or AIDS~* Pregnant or breastfeeding~* Receiving activated Vitamin D analogs, nutritional vitamin D agents \> 2,000 IU/day, or calcimimetics with in the last 3 months~* Significant GI disorder~* Proteinuria \>3.5 g/24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevelamer carbonate (Type: EXPERIMENTAL): 1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
- Calcium acetate (Type: ACTIVE_COMPARATOR): 1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).